The prognostic value of CINSARC in a randomised trial comparing histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001).

被引：0

作者：

Pasquali, Sandro

Braglia, Luca

Chibon, Frederic

Coindre, Jean Michel

Italiano, Antoine

Romagosa, Cleofe

Bague, Silvia

Dei Tos, Angelo Paolo

Palmerini, Emanuela

Quagliuolo, Vittorio

Broto, Javier Martin

Lopez-Pousa, Antonio

Grignani, Giovanni

Brunello, Antonella

Blay, Jean-Yves

Beveridge, Robert Diaz

Stacchiotti, Silvia

Merlo, Domenico F.

Casali, Paolo Giovanni

Gronchi, Alessandro

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Milan, Italy

[2] IRCCS Azienda Osped Univ San Martino, Ist Ist Nazl Ric Sul Canc, Clin Trial Ctr, Genoa, Italy

[3] IRCCS Azienda Osped Univ San Martino, Ist Ist Nazl Ric Sul Canc, Dept Epidemiol, Genoa, Italy

[4] Inst Bergonie, Bordeaux, France

[5] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France

[6] H Vall dHebron, Barcelona, Spain

[7] Hosp St Pau & Santa Creu, Pathol Dept, Barcelona, Spain

[8] Padua Univ Hosp, Padua, Italy

[9] IRCCS Ist Ortoped Rizzoli, Bologna, Italy

[10] Ist Clin Humanitas, Milan, Italy

[11] Univ Seville, Inst Biomed Res IBIS, CSIC, Virgen del Rocio Univ Hosp, Seville, Spain

[12] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[13] IRCCS, FPO, Candiolo Canc Inst, Div Med Oncol, Candiolo, TO, Italy

[14] Ist Oncol Veneto IOV IRCCS, Dept Oncol, Med Oncol Unit 1, Padua, Italy

[15] Ctr Leon Berard, Unicanc, Lyon, France

[16] Med Oncol Dept, Valencia, Spain

[17] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[18] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Adult Mesenchymal & Rare Tumor Unit, Milan, Italy

[19] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Sarcoma Serv, Milan, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e23531

引用

页数：2

共 50 条

[41] A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: DARLING-02
Zhang, Lina
Geng, Cuizhi
Liu, Yueping
Han, Jianjun
Han, Meng
Huang, Ruixue
Li, Xianqiao
Luo, Ruizhen
Li, Yuntao
Ma, Jie
Qi, Huaihua
Wang, Zunyi
Wang, Xiaochun
Yang, Chao
Yang, Jingqiang
Yang, Lixian
Yu, Jingjing
Zhang, Yingzhou
Zhang, Zhisheng
Zhou, Xinping
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial
Blay, Jean-Yves
Papai, Zsuzsanna
Tolcher, Anthony W.
Italiano, Antoine
Cupissol, Didier
Lopez-Pousa, Antonio
Chawla, St P.
Bompas, Emmanuelle
Babovic, Nada
Penel, Nicolas
Isambert, Nicolas
Staddon, Arthur P.
Saada-Bouzid, Esma
Santoro, Armando
Franke, Fabio A.
Cohen, Patrick
Le-Guennec, Solenn
Demetri, George D.
LANCET ONCOLOGY, 2015, 16 (05): : 531 - 540
[43] Impact of regional hyperthermia (RHT) on response to neo-adjuvant chemotherapy and survival of patients with high-risk soft-tissue sarcoma (HR-STS): Results of the randomized EORTC-ESHO intergroup trial (NCI-00003052)
Issels, R.
Lindner, L. H.
Wendtner, C. M.
Hohenberger, P.
Reichardt, P.
Daugaard, S.
Mansmann, U.
Hiddemann, W.
Blay, J. Y.
Verweij, J.
EJC SUPPLEMENTS, 2009, 7 (03): : 2 - 2
[44] Risk assessment of early progression among 213 pts with high-risk soft tissue sarcomas (HR-STS) treated with neoadjuvant chemotherapy ± regional hyperthermia:: EORTC 62961/ESHO-RHT 95 intergroup phase III study.
Lindger, LH
Schlemmer, M
Hohenberger, P
Wust, P
Schmidt, M
Verweij, J
Judson, I
Jauch, KW
Hiddemann, W
Issels, RD
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 821S - 821S
[45] Long-Term Results of a Phase 2 Study of Neoadjuvant Chemotherapy and Radiotherapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall Radiation Therapy Oncology Group Trial 9514
Kraybill, William G.
Harris, Jonathan
Spiro, Ira J.
Ettinger, David S.
DeLaney, Thomas F.
Blum, Ronald H.
Lucas, David R.
Harmon, David C.
Letson, G. Douglas
Eisenberg, Burton
CANCER, 2010, 116 (19) : 4613 - 4621
[46] Full-dose neoadjuvant anthracycline plus ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial
Gronchi, A.
Ferrari, S.
Quagliuolo, V.
Martin Broto, J.
Lopez-Pousa, A.
Grignani, G.
Ferraresi, V.
Blay, J-Y.
Rutkowski, P.
Merlo, F. D.
Marchesi, E.
Ledesma, P.
Tos, A. P. Dei
Rosell, S. Bague
Coindre, J-M.
Morosi, C.
Stacchiotti, S.
Picci, P.
Bruzzi, P.
Casali, P. G.
ANNALS OF ONCOLOGY, 2016, 27
[47] Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).
Gronchi, Alessandro
Palmerini, Emanuela
Quagliuolo, Vittorio
Broto, Javier Martin
Pousa, Antonio Lopez
Grignani, Giovanni
Brunello, Antonella
Blay, Jean-Yves
Beveridge, Robert Diaz
Ferraresi, Virginia
Lugowska, Iwona
Merlo, Franco Domenico
Fontana, Valeria
Palassini, Elena
Morosi, Carlo
Stacchiotti, Silvia
Dei Tos, Angelo Paolo
Picci, Piero
Bruzzi, Paolo
Casali, Paolo Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[48] Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group
Gronchi, A.
Stacchiotti, S.
Verderio, P.
Ferrari, S.
Broto, J. Martin
Lopez-Pousa, A.
Llombart-Bosch, A.
Tos, A. P. Dei
Collini, P.
Cruz Jurado, J.
De Paoli, A.
Donati, D. M.
Poveda, A.
Quagliuolo, V.
Comandone, A.
Grignani, G.
Morosi, C.
Messina, A.
De Sanctis, R.
Bottelli, S.
Palassini, E.
Casali, P. G.
Picci, Piero
ANNALS OF ONCOLOGY, 2016, 27 (12) : 2283 - 2288
[49] Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
Palassini, Elena
Ferrari, Stefano
Broto, Javier Martin
Verderio, Paolo
Lopez-Pousa, Antonio
Buonadonna, Angela
Miceli, Rosalba
Stacchiotti, Silvia
Dei Tos, Angelo Paolo
De Paoli, Antonino
Donati, Davide Maria
Poveda, Andres
Quagliuolo, Vittorio
Comandone, Alessandro
Bottelli, Stefano
Picci, Piero
Casali, Paolo Giovanni
Gronchi, Alessandro
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[50] Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma The EORTC 62961-ESHO 95 Randomized Clinical Trial
Issels, Rolf D.
Lindner, Lars H.
Verweij, Jaap
Wessalowski, Rudiger
Reichardt, Peter
Wust, Peter
Ghadjar, Pirus
Hohenberger, Peter
Angele, Martin
Salat, Christoph
Vujaskovic, Zeljko
Daugaard, Soeren
Mella, Olav
Mansmann, Ulrich
Durr, Hans Roland
Knosel, Thomas
Abdel-Rahman, Sultan
Schmidt, Michael
Hiddemann, Wolfgang
Jauch, Karl-Walter
Belka, Claus
Gronchi, Alessandro
JAMA ONCOLOGY, 2018, 4 (04) : 483 - 492

← 1 2 3 4 5 →